NL-OMON37629已完成不适用
A Single-Center, Randomized, Observer-Blinded, Placebo-Controlled, Single-Ascending-Dose (SAD) Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5469754, a Humanized Monoclonal Antibody, Following Intravenous or Subcutaneous Administration in Healthy Adults - RO5469754 monoclonal antibody study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 56
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Healthy male or female
- •age: 18-64 yrs, inclusive
- •BMI: 18-32 kg/m2, inclusive
排除标准
- •Suffering from: hepatitis B, cancer or HIV/Aids. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 90 days from the start of the study. In case of donating more than 1.5 liters blood in the 10 months preceding the start of the study (male)/ more than 1.0 liters of blood in the 10 months preceding the start of the study (female).
研究者
相似试验
进行中（未招募）
不适用
Effectiveness and safety of Xen2174 in controlling pain after bunion surgeryModerate to severe acute post-operative pain in subjects following primary unilateral first metatarsal bunionectomyMedDRA version: 14.1Level: SOCClassification code 10028395Term: Musculoskeletal and connective tissue disordersSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2010-019109-40-BGXenome Ltd150
已完成
不适用
A investigator study to evaluate the effect of gait rehabilitation using a rehabilitation robot(Healbot T) on walking ability for stroke patientsKCT0003762Asan Medical Center52
已完成
Unknown
To study the colur, thickness, taste, smell of a syrup in children.CTRI/2023/04/052120Cipla Ltd.55
进行中（未招募）
1 期
Comparison of two cardiac protection techniques during cardiac surgeryMedical conditions necessitating an elective surgical coronary arterybypass grafting (CABG) and/or a valve repair/replacement.EUCTR2011-004198-10-ATSwiss Cardio Technologies AG264
进行中（未招募）
不适用
A Randomised, Observer-blind, Multicentre, Non-inferiority, Comparative Study of the Safety and Efficacy of Topical 1% SB-275833 Ointment, Applied Twice Daily for 5 Days, versus Topical 2% Sodium Fusidate Ointment Applied Three Times Daily for 7 Days in the Treatment of Adult and Paediatric Subjects with ImpetigoMedDRA version: 7.1Level: PTClassification code 10021531ImpetigoEUCTR2004-004439-70-DEGlaxSmithKline Research & Development520